Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phase

Overview of attention for article published in Cost Effectiveness and Resource Allocation, July 2021

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 7 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 2,178 followers.

Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phase https://t.co/8uN9ueLXLE

20 Jul 2021

Reply Repost Favourite

Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phase https://t.co/JMBMrIZ4v1

19 Jul 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.